Table 1 |
||
|
Clinical, histological, phenotypical and molecular findings in the series of 82 FL |
||
|
Gender |
F |
46 |
|
M |
36 |
|
|
|
||
|
Age |
Median 58 |
Range 20-88 |
|
|
||
|
Type of FL |
Nodal FL |
67 |
|
Combined FL+DLBCL |
10 |
|
|
Cutaneous |
5 |
|
|
|
||
|
Pattern |
"In situ neoplasia" |
6 (7.8%) |
|
Nodular |
62 (80.5%) |
|
|
Nodular and diffuse |
5 (6.5%) |
|
|
Diffuse |
4 (5.2%) |
|
|
|
||
|
WHO Grade |
Grade 1 |
8 (11.3%) |
|
Grade 2 |
37 (52.1%) |
|
|
Grade 3 |
26 (36.6%) |
|
|
|
||
|
Marginal differentiation |
Yes |
7 (9.9%) |
|
No |
64 (90.1%) |
|
|
|
||
|
BCL6 |
Positive |
76 (92.7%) |
|
Negative |
6 (7.3%) |
|
|
|
||
|
CD10 |
Positive |
74 (90.2%) |
|
Negative |
8 (9.8%) |
|
|
|
||
|
BCL2 |
Positive |
72 (87.8%) |
|
Negative |
10 (12.2%) |
|
|
|
||
|
Ki67 antigen |
Low |
23 |
|
Intermediate |
30 |
|
|
High |
29 |
|
|
|
||
|
IGH gene rearrangement |
Monoclonal |
66 (80.5%) |
|
Polyclonal |
16 (19.5%) |
|
|
|
||
|
MBR-BCL2/JH rearrangement |
Present |
19 (23.2%)/15 (27.3%)* |
|
Absent |
63 (76.8%)/40 (72.7%)* |
|
|
|
||
|
* Limited to cases with successful beta-globin gene amplification. |
||
|
Goteri et al. Diagnostic Pathology 2011 6:97 doi:10.1186/1746-1596-6-97 |
||
